Guidelines and Recommendations Towards Evidence-Based Management of Systemic Sclerosis

Devakandan, Keshini

doi:10.1007/s40674-019-00120-2

Cited by 1 publication

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is currently no consensus regarding treatment initiation or escalation [89]. Most SSc experts draw on their clinical experience and consider the risk factors for SSc-ILD progression to inform their decision on when to initiate therapy on a case-by-case basis [90].…”

Section: Implications For Therapymentioning

confidence: 99%

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Assassi²,

et al. 2020

Self Cite

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.There are no valid biomarkers to predict the occurrence of SSc-ILD, although auto-antibodies against anti-topoisomerase I and several inflammatory markers are candidate biomarkers that need further evaluation. Chest auscultation, presence of shortness of breath and pulmonary function testing are important diagnostic tools, but lack sensitivity to detect early ILD. Baseline screening with high-resolution computed tomography (HRCT) is therefore necessary to confirm an SSc-ILD diagnosis. Once diagnosed with SSc-ILD, patients' clinical courses are variable and difficult to predict, although certain patient characteristics and biomarkers are associated with disease progression. It is important to monitor patients with SSc-ILD for signs of disease progression, although there is no consensus about which diagnostic tools to use or how often monitoring should occur. In this article, we review methods used to define and predict disease progression in SSc-ILD.There is no valid definition of SSc-ILD disease progression, but we suggest that either a decline in forced vital capacity (FVC) from baseline of ≥10%, or a decline in FVC of 5–9% in association with a decline in diffusing capacity of the lung for carbon monoxide of ≥15% represents progression. An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1–2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.

show abstract

Section: Implications For Therapymentioning

confidence: 99%